CD69 Antilichaam [H1,2F3] (FITC)

CD69, also known as very early activation (VEA) antigen, is a disulfide-linked transmembrane homodimer whose differentially glycosylated subunits range from 35-39 kDa. It is a C-type lectin most closely related to the NKR-P1 and Ly-49 NK cell-activation molecules. CD69 is widely expressed on hematopoietic cells, including lymphocytes, neutrophils and eosinophils. Although not detectable on resting lymphocytes, its expression is rapidly upregulated upon activation of T, B and NK cells, and neutrophils. Constitutive expression of CD69 on subsets of thymocytes suggests that it may be involved in regulation of developmental events in addition to its role in activation of a variety of hematopoietic cells. The monoclonal antibody H1.2F3 augments PMA-induced T-cell proliferation and induces redirected lysis of Fc receptor-bearing target cells by NK cells.

12515

P37217

P37217

Mouse

Mouse dendritic epidermal cell line Y245

[H1.2F3]

FITC

Primary Antibodies

Immunology

0.5 mg/mL

Supplied in PBS/NaN3

None

Blue Ice

Store vial at 2-8˚ C

IgG

CD69

CD69 Antibody [H1.2F3] for use in flow cytometry and immunohistochemistry assays.

Cd69

CD69 antigen

Mus musculus

VEA, very early activation antigen, AIM, EA1, MLR3, gp34/28, Leu-23

IHC-Fr, Flow, IP

Liquid